Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 10/01/2018
Entire Document
 


In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: August 1, 2018 - August 31, 2018

 

MOR - 2

Statement of Operations

For the Period: August 1, 2018 - August 31, 2018

(Unaudited)

 

$ USD ‘000s

   August 1, 2018 - August 31, 2018     March 12 - August 31, 2018  

Net product sales

   $ —       $ 27,871  

Cost of product sales

     —         (6,336

Operating expenses:

    

Research and development

     (8     (2,674

Selling, general and administrative

     (74     (32,262

Amortization expense of intangible assets

     —         (2,987
  

 

 

   

 

 

 

Total operating expenses

     (81     (37,924
  

 

 

   

 

 

 

Loss from operations

     (81     (16,389

Other income/(expense):

    

Interest income

     21       705  

Refundable tax credit(1)

     —         1,300  

Interest expense

     —         (728
  

 

 

   

 

 

 

Total other income (expenses)

     21       1,276  
  

 

 

   

 

 

 

Net loss

     (60     (15,112

Reorganization expenses(2)

     552       (312,264
  

 

 

   

 

 

 

Net gain/(loss)

   $ 492     $ (327,377
  

 

 

   

 

 

 

Notes:

 

(1)

Refundable tax credit includes refundable alternative minimum tax as created by the Tax Cuts and Jobs Act.

(2)

Reorganization expenses include the loss on sale of assets as well as the write up of the notes to the principle balance, the elimination of the debt discount and debt costs related to the 2013 debt. The loss on sale of assets is not final and pending the completion of a valuation of the non-debtor subsidiaries.